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Abstract
Cannabis is one of the oldest psychotropic drugs known to humanity. The paper assesses the
current knowledge on the cannabis, including the mechanisms of action and the therapeutic potential of
cannabinoids.
Three varieties of Cannabis plant are recognised: Cannabis sativa, Cannabis indica, and
Cannabis ruderalis. The variety indica is used predominantly to obtain the drugs. Cannabis herb is
usually named marijuana, while the cannabis oleoresin secreted by the glandular hairs found mainly on
the flowering or fruiting tops of the plant is known as hashish. More than 400 known chemicals are
present in cannabis, at least 70 of which are called cannabinoids. The major psychoactive constituent in
cannabis is delta-9-tetrahydrocannabinol (Δ9-THC). It is now recognized that there are three types of
cannabinoids: natural (phytocannabinoids), endogenous cannabinoids, and synthetic cannabioids.
Cannabinoids exert their actions by binding to specific membrane protein, the cannabinoid
receptor. To date, two subtypes of cannabinoid receptors, named cannabinoid-1 (CB1), most
abundantly expressed in the central nervous system and cannabinoid-2 (CB2) receptors, found
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predominantly in peripheral tissues with immune functions have been cloned. Therefore, the concept of
endogenous cannabinoid system (endocannabinoid system, SEC) has been developed. Based on the
current scientific evidence, there are several effects of cannabinoids with potential therapeutic use:
antiemetic, analgesic in cancerous pains, and chronic neuropathic pain, in multiple sclerosis or spinal
cord injuries.
Cannabis consume can result in a state of drug dependency and cannabis withdrawal has been
included in DSM-V. Cannabis plant remains controversial in the twenty-first century and the potential
therapeutic of specific cannabinoid compounds and medical marijuana remains under active medical
research.

Introduction
Drugs from Cannabis are currently used extensively and illicit and have a long history of use
from ancient times. Originating from Central Asia, Cannabis one of is the oldest cultivated textile plant,
as well as a psychotropic drugs known to humanity. It has been known by the peoples of south-east
Asia for over 4,000 years, as evidenced by vessels found in China, which are painted with strains of
Cannabis (1).
The first therapeutic use of cannabis as a sedative in rheumatic pain and gout has been
described in the compendium of Chinese medicinal herbs elaborated by the Emperor of China, Shen
Nung (2737 BC). Medical uses of cannabis were mentioned in the nineteenth century in a paper
published in 1842 by the Irish physician William O'Shaughnessy, who validated folk uses of cannabis
in India, and discovered new applications, recommending cannabis for a great variety of therapeutic
purposes, such as analgesic, appetite stimulant, antiemetic, muscle relaxant and anticonvulsant (2).
In 1854, cannabis was listed in the United States Dispensatory. In 1942, cannabis was removed
from the United States Pharmacopoeia. Cannabis was also available in the British Pharmacopoeia in
extract and tincture form for over 100 years. In 1964 (-)-trans-delta-9-tetrahydrocannabinol (delta-9THC, dronabinol), the principal active ingredient of cannabis, was stereochemically defined.
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Cannabis was banned in 1961 by adopting the Single Convention on Narcotic Drugs instituted
by the United Nations. Cannabis and cannabis resin, extracts and tinctures of cannabis were placed
under the heaviest control regime in the Convention, Schedule I (3).
Worldwide, cannabis is the most commonly used illicit substance. According to the current
statistics (World Drug Report, 2014, elaborated by the United Nations Office on Drugs and Crime), in
2012, between 125 million and 227 million people (corresponding to between 2.7 and 4.9 per cent of
the population aged 15-64 years) were estimated to have used cannabis (4). In Europe, in contrast to
elsewhere, the overall use of cannabis appears to be stable or even declining, with 73.6 million (21.7%
of population aged 15-64 years) using cannabis in their lifetime (European Monitoring Centre for Drug
and Drug Addiction, European Drug Report, 2014) (5).

Discussion
Cannabis drugs
The plant Cannabis is the source of a number of abuse drugs, such as marijuana or hashish. The
unique properties of the plant Cannabis have generated much debate on the taxonomic classification.
Cannabis was reclassified several times before assigning its own family (Cannabinaceae), which
includes only hops plant. However, the widespread opinion is that the Cannabis plant is presented as
three varieties: Cannabis sativa, Cannabis indica, and Cannabis ruderalis, originating in Central Asia,
Southeast Asia and surrounding regions. Cannabis sativa variety, with spreading in the temperate
continental areas, is commonly used for textile fibbers and seeds; Cannabis indica variety, cultivated in
tropical areas, is valued predominantly for the oleoresins containing psychoactive substances and is
used to obtain the drugs (1).
Cannabis is a generic term for the drugs obtained from the plant Cannabis. Usually, Cannabis
designates the dried vegetal material (“Cannabis herb”, the name usually in slang, marijuana). Hashish
or ”hash” represents the cannabis resin, secreted by the glandular hairs found all over the plant but
mainly around the flowers. Hashish oil is the extract from Cannabis or hashish, using a solvent (e.g.
30
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acetone) and evaporated. The cannabis plant can be used as a source of hemp fibres, as well as hemp
seeds and fatty oil (6).
According to the Single Convention on Narcotic Drugs (United Nations 1961) Cannabis
represents the flowering or fruiting tops of the cannabis plant (excluding the seeds and leaves when not
accompanied by the tops) from which the resin has not been extracted; Cannabis resin is the separated
resin, whether crude or purified, obtained from the Cannabis plant. These definitions are based on
traditional Indian terms ganja (cannabis) and charas (resin) (3). Ganja/ganga refers to the small upper
leaves and flowering tops of the cultivated flowering plants. Another Indian term, Bhang represents the
dried leaves and flowering tops of the uncultivated female cannabis plant, smoked or consumed as a
beverage in the Indian subcontinent.
Routes of administration
Smoking is the most common way of cannabis use (often mixed with tobacco). Marijuana is
typically smoked as a joint, but it can be prepared in food for oral consumptions, as in brownies,
cookies, or spaghetti. Bhang is used as an infusion in the Indian subcontinent. Because THC has low
water solubility, ingestion of cannabis leads to poor absorption.
The “typical” marijuana cigarette is obtained from a gram of C sativa leaves and buds and
contains about 20 mg of THC. The resin (hashish) is also smoked in a smoking device (bong), while
the liquid cannabis (hashish oil) is used by smoking, vaporization, or may be consumed orally.
Chemical components of Cannabis
It is recognized that there are about 400 chemicals in hemp resin secreted by the flowering tops
and leaves of female plants; this resin contains at least 70 chemicals, terpenophenolic derivates, called
cannabinoids. Small amounts are found in the stems; the seeds do not contain cannabinoids.
The major psychoactive constituent in cannabis is delta-9-tetrahydrocannabinol (Δ9-THC), which is
formed in plant during biosynthesis of natural cannabinoids. To synthesize THC, the plant needs a high
average temperature, during flowering, daily over 35°C.
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There are three types of cannabinoids:
 natural cannabinoids (phytocannabinoids, Figure 1), such as Δ9-THC), cannabidiol (CBD), a major
constituent without psychoactive properties, but with anticonvulsant, anxiolytic and antiinflammatory activity, delta-9-tetrahydrocannabivarine (Δ9-THCV, the analog of THC with propyl
radical), a CB1 receptor antagonist, which attenuates the psychoactive effects of THC. Other
cannabinoids present in Indian hemp include delta-8-tetrahydrocannabinol (Δ8-THC), cannabinol
(CBN), cannabicyclol (CBL), cannabichromene.
 endogenous cannabinoids, that include arachidonic acid derivatives; the two most researched
endocannabinoids are anandamide (arachidonoyl ethanolamide, AEA) and 2-AG (2-arachidonoyl
glycerol).

Δ9-THC

Canabidiol

Canabinol

Δ9-THCV

Figure 1. The chemical structures of some phytocannabinoids
 synthetic cannabinoids, functionally similar to Δ9-THC and initially developed over the past 40
years to be used as therapeutic agents, often for the treatment of pain. In the late of 2008, several
synthetic cannabinoids were detected in herbal smoking mixtures or so-called incense/room
odorisers. Spice Gold, Spice Silver and Yucatan Fire are typically sold via the Internet and in ‘head
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shops’. In December 2008, the synthetic cannabinoid JWH-018 was identified in spice; presumably,
a solution of the cannabinoids is sprayed onto the herbal mixture. Currently, little is known about the
detailed pharmacology and toxicology of the synthetic cannabinoids and few formal human studies
have been published. It is possible that, apart from high potency, some cannabinoids could have
particularly long half-lives potentially leading to a prolonged psychoactive effect; in addition, there
is a higher potential for overdose than with cannabis.
Potential therapeutic uses of cannabinoids
Based on current scientific evidence, therapeutic effects of cannabis and/or THC (dronabinol, the
levorotatory isomer of synthetic trans delta-9-THC), can be classified as follow (7):
1. proven effects: antiemetic, useful in nausea and vomiting caused by chemotherapy; appetite
stimulant, useful in anorexia and weight loss in patients with devastating diseases (eg. AIDS).
2. effects relatively well documented: the spasms, pain, movement disorders, asthma, and glaucoma.
3. unproven effects: in allergies, itching, inflammation and infection, epilepsy, depression, anxiety.
4. effects under basic research: the self-resistant disease, cancer, neuroprotection, abnormal blood
pressure
The problems inherent in the therapeutic use of cannabis are focused on his legal position as
prohibited drug, which applies in most parts of the world, and on the smoking use, plus the uncertainty
about the composition and purity of raw cannabis. In most countries, the legal classification is based on
the premise that cannabis use has no demonstrable therapeutic benefit (although dronabinol and
nabilone, a synthetic cannabinoid, are approved for clinical use), and rather limits opportunities for
appropriate clinical evaluation.
According to Ben Amar, in the review published in 2006, there are ten pathologies and conditions with
proven cannabinoids use and published controlled clinical trials (Figure 2) (2).
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Figure 2. The therapeutic potential of cannabinoids
A number of cannabis products are being manufactured by pharmaceutical companies,
including Marinol (dronabinol; THC), Cesamet (nabilone), and Sativex (THC + CBD). Dronabinol
(Marinol®), a synthetic THC, and its analogue nabilone (Cesamet ®) have been approved in Canada and
USA for many years, for chemotherapy-associated emesis in patients who had not responded to
conventional antiemetic medications. These medicines were also approved for use in anorexia
associated with weight loss in patients with AIDS (8).
The drug product Sativex, oromucosal spray (manufactured by GW Pharmaceuticals), a
cannabis plant extract consisting of equal amounts of dronabinol (THC) and cannabidiol (Nabiximols,
THC + CBD) received approval in UK as an adjunctive treatment for multiple sclerosis patients (is
used to alleviate neuropathic pain, spasticity, overactive bladder, and other symptoms); it is also
developed in Phase III trials as a potential treatment to alleviate pain in cancer.
Medicinal cannabis
Since July 2001, the Marihuana Medical Access Regulations (MMAR) allow Canadian patients
suffering from a serious disease to be eligible for therapeutic marijuana consumption. The medicinal
cannabis, with standard cannabinoid concentrations, has been sold in pharmacies in the Netherlands by
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medical prescription. There are several side effects of the medicinal cannabis: mood-altering effects,
insomnia and heart palpitations.
The genetic predisposition to psychosis (like schizophrenia) or other mental health problems are
listed as precautions. In addition, smoking medicinal cannabis is not recommended due to the risk of
damages to lungs); instead, inhaling cannabis using a reliable vaporiser is a more suitable method.
Mechanisms of cannabinoids action
Cannabinoids exert their actions by binding to specific membrane protein: the cannabinoid
receptors (part of the G-protein coupled class; their activation results in inhibition of adenylate cyclase
activity). Based on the lack of stereospecificity Δ9-THC activity, and its lipophilicity, the molecular
mechanisms of action of cannabinoids were initially considered nonspecific, of anesthetic type. The
most impressive discovery on cannabis study was the identification in 1991 of the first endogenous
receptor for THC, the CB1 receptor. The experimental observation that THC inhibits, reversible,
stereoselective and dose dependent manner, adenylate cyclase in neuroblastoma cells led to the
hypothesis of receptor mediated interaction for THC. The first endogenous ligand for the CB1 receptor,
arachidonyl ethanolamide (AEA, anandamide, name in Sanskrit ananda = "bringer of inner happiness")
was discovered in 1992. This was followed by the identification of other types and subtypes of
endougenous receptors (CB2 receptor, with predominantly peripheral localization), as well as natural,
synthetic or endogenous substances with affinity for these receptors. Therefore, the concept of
endogenous cannabinoid system (endocannabinoid system, SEC) has been formulated. Consequently,
the functions of this system in the body have been studied and the attempts to synthesize of substances
that activate or antagonize the SEC have been made.
The other putative endocannabinoids are 2-arachidonylglycerol (2-AG), O-arachidonyl
ethanolamine (virodhamine), N-arachidonyl dopamine (NADA), and 2-arachidonyl glyceryl ether (2AGE, noladin ether). AEA and NADA are also shown to have an affinity to transient receptor potential
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vanilloid 1 (TRPV1) receptors (9). In contrast to anadamide and 2-AG (which binds to both the CB1
and CB2 receptors), 2-AGE binds very weakly to CB2 receptors.

Cannabinoid
receptors

CB1 (central):
basal ganglia, hippocampus,
cerebellum

CB2 (peripheral):
spleen, tonsils, B and T
lymphocytes

Effects on memory, perception and

Immunosuppressive

motion control

effects

Figure 3 The cannabioids receptors
Cannabis and THC mode of action THC is absorbed rapidly across the large surface area of the
lungs and takes 10 – 30 min. To reach peak plasma concentration; it is deposited in organs with high fat
content (such as brain) due to its lipid solubility. THC and its metabolites can remain in the body for up
to 30 days; repeated administration can lead to accumulation. When smoked, the effects can last for up
to four hours, depending of the amount used.
Cannabis intoxication. Schematically, there are four stages of Cannabis intoxication: excitation,
mental instability and hallucinations, ecstatic phase, and deeply rest. Cannabis intoxication is a
syndrome described in DSM-V and ICD-10, with psychological / behavioral and physical
manifestations (Table 1) (10).
Psychological and behavioural effects

Physical effects

Euphoria, relaxation,wellbeing, self-confidence

Nausea and vomiting, dry mouth, hunger
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Changes in perception of time, intensified Red eyes, swollen eyelids
visual and auditory perception
Enhancement of taste, touch, smell

Motor incoordination

Concentration and memory may be impaired

Tachycardia, Orthostatic hypotension

The experience may not be plesurable (anxiety,
paranoia and agitation, and occasionally panic
reactions)

Table 1 Manifestations of cannabis intoxication
Long term effects
Frequent inhalation of cannabis smoke over a period of years will contribute toward bronchitis
and other respiratory disorders and possible cancer of the lung and parts of the digestive system; risks
are greater if is smoked with tobacco.
Impaired endocrine function was associated with cannabis use. Long term, high doses may
result in reduced fertility in females and reduced testosterone and sperm count in males. Cannabis
consumption may increase the probability of psychotic symptoms in vulnerable individuals (with a
history of schizophrenia, and depending on individual predisposing factors and use of other substances)
(11).
Persistent disturbance of cognitive functions and memory, risk of malformations in newborns,
and immunosuppressant effects have been also cited as secondary effects of long term cannabis use.
Discussion of adverse effects is often focused on the “amotivational” syndrome, resulting in lower
school averages and higher dropout rates among users than non-users. This aspect is controversial, and
the syndrome has not been officially diagnosed. Conflicting evidence exists of any cannabis “gateway”
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effect (escalation theory suggesting that using drugs such as cannabis leads to consumption of more
harmful drugs).
Cannabis dependence
Typically, few consumers fulfil DSM criteria for cannabis dependence (typically those who
smoke marijuana daily and with personal or family history of addiction to psychoactive substances);
most often is diagnosed cannabis abuse. However, when there is a significant level of tolerance or
mental and physical problems associated with compulsive consumption context, it is necessary
diagnosis of dependence, not abuse.
Tolerance, physical dependence
The development of tolerance and dependence to cannabis is a controversial issue and has not
been fully established. Psychological dependence can result in chronic users of cannabis. Although
regular users who stop smoking cannabis do not experience a withdrawal syndrome as opioid users,
when used is in high quantities, there have been reports of abstinence (withdrawal) syndrome
indicating physical dependence. DSM-IV-TR describes two cannabis use disorders (cannabis
dependence and abuse) and six categories of cannabis-induced disorders (cannabis dependence,
cannabis abuse, cannabis-induced disorders, cannabis intoxication, cannabis intoxication delirium,
cannabis-induced psychotic disorder, with delusions, cannabis-induced psychotic disorder, with
hallucinations, cannabis-induced anxiety disorder, and cannabis-related disorder not otherwise
specified), while DSM-V has included cannabis withdrawal (8); the syndrome developing within 48 h
of cessation is reported by up to one-third of regular users in the general population and by 50%–95%
of heavy users in treatment or research studies (12). The commonest signs and symptoms of cannabis
withdrawal syndrome include decreased appetite, insomnia, weight loss, irritability, restlessness,
anxiety, aggression. Withdrawal symptoms tend to subside in 2–12 weeks after cannabis abstention.
Treatment No medication has been shown broadly effective in the treatment of cannabis
dependence, nor is any medication approved for this condition by any regulatory. Naloxone has been
shown to block the reward effects of THC, in preclinical studies. Depending on the severity of
symptoms, the antidepressant medication can be useful.
38

Cannabis abuses and therapeutic effects

Conclusions
Known for thousands of years, Cannabis plant remains disputed and controversial in the twentyfirst century. In addition, the potential therapeutic of specific cannabinoid compounds remains under
medical research and larger clinical trials are also needed to assess the benefits and risks of medical
marijuana.
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